Drug intelligence / Profile preview

XON9

Development stage: Preclinical
Lead developer: Xenothera
Modality: Antibody-Based Therapeutics
Administration: Parenteral

Overview

XON9 is a preclinical-stage glyco-humanized polyclonal antibody (GH-pAb) being developed by Xenothera for the treatment of solid tumors and hematologic malignancies. The drug is produced using Xenothera's proprietary platform, which involves the production of antibodies in animals genetically modified to lack specific immunogenic sugars (such as Neu5Gc), followed by a humanization process. This approach is intended to combine the multi-target efficacy of polyclonal antibodies with the safety and low immunogenicity profile of humanized monoclonal antibodies. XON9 is currently undergoing preclinical evaluation to support its advancement into clinical trials for oncology indications.

Targets

FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)Complement (Complement system)

Beyond the preview

Go deeper on XON9.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XON9.

Explore the full profile